Recent Reports

Evidence report on anti-androgen drugs for high risk prostate cancer. This report will serve as the basis for discussion during a public meeting of Midwest CEPAC in September 2018.

View More on this Topic

ICER’s Draft Evidence Report, open to public comment until September 20, 2018. For more information on submitting a public comment, please visit our stakeholder engagement page.

View More on this Topic

ICER’s Draft Evidence Report on treatments for hereditary transthyretin-related amyloidosis, open to public comment until August 17, 2018 at 5pm ET. For more information on submitting a public comment, please visit our stakeholder engagement page.

View More on this Topic



Materials

New England CEPAC

Sickle Cell Disease: Open Input Period

ICER

Valuing a Cure: Draft Methods Adaptations

ICER

Valuing a Cure: Technical Brief

Health Economist

CTAF

Peanut Allergy: Report-at-a-Glance

Program Manager

CTAF

RA Update: Updated Scoping Document

CTAF

Osteoporosis: Report-at-a-Glance (Spanish)

Midwest CEPAC

Multiple Sclerosis: Report-at-a-Glance (Spanish)

CTAF

Migraine: Report-at-a-Glance (Spanish)

New England CEPAC

Opioid Use Disorder: Report-at-a-Glance (Spanish)

CTAF

Hereditary Angioedema: Report-at-a-Glance (Spanish)